Qyuns Therapeutics Co., Ltd. (02509) disclosed a share repurchase on 16 January 2026. The company repurchased 45,000 ordinary shares, resulting in an adjusted total of 225,286,000 issued shares (excluding treasury shares) and 1,785,600 treasury shares as of the same date. The repurchase price ranged between HKD 22.98 and HKD 23.32 per share, with an aggregate consideration of HKD 1,041,174.

The repurchase was conducted under a mandate dated 20 June 2025, which authorized the repurchase of up to 22,207,160 shares. To date, a total of 1,785,600 shares have been repurchased under the mandate, representing approximately 0.8041% of the issued shares referenced at the time the mandate was granted.